Status and phase
Conditions
Treatments
About
To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.
Full description
All patients receive a single dose of SnET2 and are randomized to receive either PDT light treatment or no light treatment (control group). Patients are assessed prior to and at 4, 12 and 24 weeks following treatment, and are followed for 7 months.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
Excluded within 7 days of therapy:
Excluded within 3 months of therapy:
Excluded within 6 months of therapy:
Prior Medication:
Excluded:
Prior Treatment:
Excluded within 3 months prior to therapy:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal